Rosacea - Pipeline Review, H2 2017

Published: Oct, 2017 | Pages: 63 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rosacea - Pipeline Review, H2 2017, provides an overview of the Rosacea (Dermatology) pipeline landscape.

Rosacea is a chronic and potentially life-disruptive disorder primarily of the facial skin, often characterized by flare-ups and remissions. Symptoms include frequent redness of the face, or flushing, small, red lines under the skin, a swollen nose and thick skin, usually on the forehead, chin, and cheeks. The predisposing factors include age and family history of rosacea. Treatment includes antibiotics and acne drugs.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Rosacea - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Rosacea (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rosacea (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Rosacea and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 7, 7 and 1 respectively.

Rosacea (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Rosacea (Dermatology).
- The pipeline guide reviews pipeline therapeutics for Rosacea (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Rosacea (Dermatology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Rosacea (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Rosacea (Dermatology)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Rosacea (Dermatology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Rosacea (Dermatology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Rosacea - Overview 7
Rosacea - Therapeutics Development 8
Pipeline Overview 8
Pipeline by Companies 9
Products under Development by Companies 11
Rosacea - Therapeutics Assessment 12
Assessment by Target 12
Assessment by Mechanism of Action 14
Assessment by Route of Administration 16
Assessment by Molecule Type 18
Rosacea - Companies Involved in Therapeutics Development 20
Almirall SA 20
Amorepacific Corp 20
BioPharmX Inc 21
Cutanea Life Sciences Inc 21
ELORAC Inc 21
Foamix Pharmaceuticals Ltd 22
Hovione FarmaCiencia SA 22
Promius Pharma LLC 23
Sol-Gel Technologies Ltd 23
Rosacea - Drug Profiles 24
AC-701 - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
ACUD-1 - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
ADP-13612 - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
benzoyl peroxide - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
carbamide peroxide - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
DFD-29 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
DMT-210 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
DMT-220 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
EP-0003 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
FMX-103 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
itraconazole - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
minocycline - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
minocycline - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
MSB-03 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
omiganan pentahydrochloride - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
PAC-14028 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
phenylbutyrate - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
Rosacea - Dormant Projects 50
Rosacea - Discontinued Products 52
Rosacea - Product Development Milestones 53
Featured News & Press Releases 53
Jun 12, 2017: Foamix Announces Dosing of First Patient in Phase 3 Rosacea Clinical Trials for FMX103 Minocycline Foam 1.5% 53
Jan 18, 2017: Dermata Therapeutics Announces Initiation of Treatment in a Phase 2 Acne Rosacea Clinical Study 53
Sep 28, 2016: Dermata Therapeutics, LLC Announces Positive Top-line Results from their Phase 1 Pharmacokinetic Study of DMT210 in Acne Rosacea Patients 54
Sep 12, 2016: Foamix Announces Positive Topline Results from Phase 2 Trial Evaluating FMX-103 Topical Minocycline Foam for Moderate-to-Severe Papulopustular Rosacea 54
Sep 09, 2016: Foamix to Announce Topline Results in Phase 2 Clinical Trial of FMX-103 Minocycline Topical Foam for Moderate-to-Severe Papulopustular Rosacea 55
May 19, 2016: Galderma Laboratories Announces Availability of New Mirvaso (brimonidine) Topical Gel, 0.33% Pump Dispenser for the Treatment of the Persistent Facial Redness of Rosacea 55
May 16, 2016: Dermata Therapeutics Announces Initiation of Phase 1 Pharmacokinetic Study 56
May 03, 2016: Foamix Announces Completion of Enrollment in Phase 2 Clinical Trial of Minocycline Foam (FMX103) for Treatment of Papulopustular Rosacea 56
Oct 20, 2015: Foamix Announces Enrollment of First Patient in Phase 2 Clinical Trial of FMX103 in Papulopustular Rosacea 57
Apr 17, 2014: Treatment for Facial Redness Associated With Rosacea Now Available in the UK 57
Feb 26, 2014: mirvaso the first and only treatment targeting the facial redness of rosacea approved by the european commission 58
Jan 29, 2014: Galderma Announces the Publication of Positive Results of the Long-Term Study of Mirvaso Gel for Treatment of Persistent Erythema of Rosacea 58
Dec 20, 2013: Galderma Receives CHMP Positive Opinion For Mirvaso 59
Sep 27, 2013: Galderma Announces Availability of Mirvaso (brimonidine) Topical Gel, 0.33% 60
Aug 26, 2013: Galderma Receives FDA Approval of Mirvaso 60
Appendix 62
Methodology 62
Coverage 62
Secondary Research 62
Primary Research 62
Expert Panel Validation 62
Contact Us 62
Disclaimer 63

List of Tables

Number of Products under Development for Rosacea, H2 2017 8
Number of Products under Development by Companies, H2 2017 10
Products under Development by Companies, H2 2017 11
Number of Products by Stage and Target, H2 2017 13
Number of Products by Stage and Mechanism of Action, H2 2017 15
Number of Products by Stage and Route of Administration, H2 2017 17
Number of Products by Stage and Molecule Type, H2 2017 19
Rosacea - Pipeline by Almirall SA, H2 2017 20
Rosacea - Pipeline by Amorepacific Corp, H2 2017 20
Rosacea - Pipeline by BioPharmX Inc, H2 2017 21
Rosacea - Pipeline by Cutanea Life Sciences Inc, H2 2017 21
Rosacea - Pipeline by ELORAC Inc, H2 2017 21
Rosacea - Pipeline by Foamix Pharmaceuticals Ltd, H2 2017 22
Rosacea - Pipeline by Hovione FarmaCiencia SA, H2 2017 22
Rosacea - Pipeline by Promius Pharma LLC, H2 2017 23
Rosacea - Pipeline by Sol-Gel Technologies Ltd, H2 2017 23
Rosacea - Dormant Projects, H2 2017 50
Rosacea - Dormant Projects, H2 2017 (Contd..1), H2 2017 51
Rosacea - Discontinued Products, H2 2017 52